Managing Partner – Sector Advisory — Diagnostic-Services Platform

The mandate

An advisory partnership is preparing succession in its diagnostic-services sector franchise. The retiring leader built trusted relationships through personal expertise, but client demand now spans payer redesign, laboratory networks, digital diagnostics and capital strategy across Asia. A planned replacement Managing Partner will convert individual reputation into a durable practice with clear intellectual positions, delivery standards and next-generation partners.

The accountable perimeter includes approximately 1,000 employees and material partners across advisory, data, clinical expertise, transactions, technology and delivery. The Managing Partner reports to the Global Managing Partner and regional partner council and owns sector strategy, client portfolio, partner economics, risk, talent and market reputation.

The sector thesis must begin with how diagnostic value is purchased. Public systems, insurers, employers and self-paying patients reward different combinations of access, test quality, turnaround, clinical interpretation and cost. The leader will help clients distinguish reimbursement pressure from genuine demand change and model how payer choices alter collection, laboratory and reporting operations.

Advice must cover the full diagnostic pathway. A laboratory productivity programme that ignores pre-analytical rejection, logistics or clinician communication can worsen economics and care. The practice will develop repeatable analyses for network footprint, test mix, capacity, equipment, workforce, quality and payer contract. Methods should be reusable without pretending that every client shares the same answer.

Origination will be issue-led. Partners should enter board conversations with a defensible view on consolidation, reimbursement, outsourcing, automation or specialist capability, not manufacture urgency to sell a large programme. The Managing Partner will review pursuit hypotheses, conflicts, access to evidence and delivery leadership before accepting work.

Independence is vital where the practice serves payers, providers, investors and suppliers. Conflict review must examine commercial relationships and confidential insight, not only legal entities. Information barriers, team exclusions or declined work may be necessary. The Managing Partner will explain such choices to important clients without delegating the difficult conversation.

Engagement economics require repair. Senior partners sometimes sell narrow diagnostics and then expand delivery without resetting scope or fees. The new leader will insist on milestone, evidence and decision definitions, with contingency explicitly authorised. Margin will reflect the senior expertise and data required; underpriced work cannot be justified by vague relationship value.

Clinical claims need qualified review. Teams advising on test utilisation, pathway design or quality controls must involve appropriate professionals and state the boundary between management advice and clinical judgement. Models should expose uncertainty and data limitations. A persuasive presentation cannot substitute for validated interpretation where patient consequence is possible.

The practice will build proprietary insight from lawful, consented and appropriately anonymised sources. Client data cannot migrate into benchmarks casually. The leader will establish provenance, permitted use, minimum aggregation and review. Where sample bias limits a market conclusion, the publication must say so rather than trade methodological caution for publicity.

Delivery quality is measured by client decisions and sustained outcomes. The Managing Partner will institute independent engagement reviews at hypothesis, recommendation and benefits stages. Teams need permission to revise the case when facts change. Cross-selling will not be counted as client impact, and claimed value must identify baseline, attribution and verification.

Partner succession is central. Sector knowledge is concentrated among a small number of senior rainmakers. The leader will assign emerging partners to real client ownership, support them in board rooms and make account transition visible in compensation. Hoarding relationships or withholding specialist talent will affect leadership standing.

The Singapore base should connect regional depth rather than centralise every answer. Country teams understand regulation, payer design and provider structure. The Managing Partner will create multi-market case teams with clear decision authority, ensure local partners receive genuine credit and avoid exporting a mature-market model without evidence.

What you will own

• Diagnostic-services sector thesis and advisory portfolio.
• Board-level origination, client stewardship and reputation.
• Payer, laboratory, technology and transaction propositions.
• Engagement acceptance, independence and delivery quality.
• Data provenance, clinical review and public insight.
• Partner economics, account transition and succession.
• Regional collaboration and specialist deployment.
• Practice profitability and risk.

The first 12 months

In the first 60 days, review the client book, conflicts, active delivery and relationship concentration. Agree account transitions with the outgoing leader and identify work whose scope, evidence or clinical review needs correction.

By month six, publish the diagnostic-sector thesis, launch two integrated propositions and appoint emerging partners to material client ownership. Introduce independent outcome reviews on priority engagements.

At twelve months, generate at least SGD 120 million of qualified sector revenue at target contribution, with 70% linked to propositions led by more than one partner. Transition 80% of priority relationships to shared ownership, maintain zero material independence breach and secure verified client outcomes on at least ten major engagements.

What the council will test

• Advice linking payer change to diagnostic operations.
• Methods reusable without formulaic client answers.
• Conflicts recognised across the healthcare ecosystem.
• Clinical assertions reviewed by qualified professionals.
• Value claims supported by attributable evidence.
• Client trust transferring beyond the incumbent leader.

The person

You bring 28+ years in strategy, transformation, transactions or professional services, with recognised diagnostic-services and payer expertise in Asia. You have led a substantial partner group, originated board-sponsored work and carried personal accountability when evidence required a difficult recommendation.

Candidates must demonstrate account succession rather than only personal sales, and experience advising laboratories, diagnostic platforms, health systems, payers or investors. Singapore is the onsite base, with extensive regional client work. Standing in the market will be verified discreetly through authorised references.

Compensation and terms

Base compensation is SGD 600,000–850,000 plus annual incentive and long-term participation tied to sector contribution, verified client outcomes, independence, partner development and relationship transition. The onsite Singapore advisory appointment reports to the Global Managing Partner and regional partner council. Succession is planned to preserve orderly client and practice continuity.

Confidentiality

The partnership, clients, engagements, partners, methods, diagnostic data and succession arrangements are confidential. Further information follows conflicts and signed confidentiality. Applicants must not approach market participants or current advisers to establish the organisation or incumbent.